Product
ADG116
Aliases
Pembrolizumab (KEYTRUDA®)
2 clinical trials
1 indication
Indication
Advanced/Metastatic Solid TumorsClinical trial
A Phase 1b, Open-Label, Dose Escalation Study of ADG116 in Combination With Pembrolizumab (Anti-PD-1 Antibody) in Patients With Advanced/Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-08-01
Clinical trial
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01